CinRx Pharma, LLC - 11 Jan 2022 Form 4 Insider Report for CinCor Pharma, Inc.

Role: 10%+ Owner
Signature: CinRx Pharma, LLC, By /s/ Jonathan Isaacsohn, CEO
Issuer symbol: N/A
Transactions as of: 11 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 13 Jan 2022, 15:40:36 UTC
Previous filing: 10 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CINC	Common Stock	Conversion of derivative security		+1,222,530	+51%		3,630,103	11 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CINC	Series A Preferred Stock	Conversion of derivative security	$0	-2,142,856	-100%	$0.000000^*	0	11 Jan 2022	Common Stock	630,251		Direct	F1
transaction	CINC	Series B Preferred Stock	Conversion of derivative security	$0	-2,013,749	-100%	$0.000000^*	0	11 Jan 2022	Common Stock	592,279		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.